Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Operating Leases (2019 - 2025)

Historic Operating Leases for Ultragenyx Pharmaceutical (RARE) over the last 7 years, with Q3 2025 value amounting to $21.7 million.

  • Ultragenyx Pharmaceutical's Operating Leases fell 831.04% to $21.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year decrease of 831.04%. This contributed to the annual value of $30.0 million for FY2024, which is 174.0% down from last year.
  • Ultragenyx Pharmaceutical's Operating Leases amounted to $21.7 million in Q3 2025, which was down 831.04% from $24.5 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Operating Leases high stood at $36.8 million for Q1 2021, and its period low was $14.8 million during Q2 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's median Operating Leases value was $27.8 million (recorded in 2025), while the average stood at $27.0 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Operating Leases plummeted by 4268.78% in 2023 and then skyrocketed by 7339.85% in 2024.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Operating Leases stood at $30.9 million in 2021, then plummeted by 35.89% to $19.8 million in 2022, then soared by 54.31% to $30.6 million in 2023, then fell by 1.74% to $30.0 million in 2024, then fell by 27.8% to $21.7 million in 2025.
  • Its last three reported values are $21.7 million in Q3 2025, $24.5 million for Q2 2025, and $27.8 million during Q1 2025.